The DOI matches its Crossref record; 32 of the 34 references it cites were found in a registry or an index.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Open accessAbstract
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms “nonalcoholic” and “fatty” were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction–associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction–associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction–associated steatotic liver disease, who consume greater amounts of alcohol per week (140–350 g/wk and 210–420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While ALD and MASLD have different aetiologies, both encompass a spectrum of liver lesions beginning with steatosis but progressing to steatohepatitis (alcohol-induced steatohepatitis; ASH or metabolic dysfunction-associated steatohepatitis; MASH, respectively) and fibrosis in some individuals.”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [200]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The two leading causes of SLD are alcohol-induced liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD); the latter being recently renamed from non-alcoholic fatty liver disease (NAFLD)(200).”
From The liver as a central "hub" of the immune system: pathophysiological implications (2025) · cites this paper as [200]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“while MAR709 requires functional GIPR signaling in the CNS to outperform GLP-1R agonism to further reduce body weight and food intake45,127, tirzepatide does not lower body weight in Glp1r-deficient mice121.”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [127]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“The histological classi fi cation was further expanded on by various scoring systems categorising steatosis, disease activity, and fi brosis [2 − 4].”
Self-citationEslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472 · cited 3×
“Indeed, there is a recognition now that there are overlapping biological processes that may contribute to both NAFLD and alcohol-associated/related liver disease (ALD).”
Self-citationNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 3×
“” [5] This important conceptual change has several practical consequences.”
Self-citationMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286 · cited 1×
“Thiswas summarised in a paper by Eslam et al., [6,7] in 2020 and led to the proposal to use the term metabolic dysfunction − associated fatty liver disease (MAFLD), which includes patients with a fatty liver regardless of the amount and pattern of alcohol intake under this terminology.”
Self-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 1×
“Moreover, this nomenclature process, in line with published guidance [21,28,29], is not advocating for the routine use of tests to con fi rm hepatic steatosis although, in reality, most, if not all, patients will usually have imaging at some point.”
Self-citationBerzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · cited 1×
“Moreover, this nomenclature process, in line with published guidance [21,28,29], is not advocating for the routine use of tests to con fi rm hepatic steatosis although, in reality, most, if not all, patients will usually have imaging at some point.”
Self-citationEddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q. M., Sheridan, D., Guha, I. N., Cobbold, J. F., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,410 · cited 1×
“Such cases and also cryptogenic cases that subsequently manifest CMRF can be rebadged as MASLD.”
Self-citationTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Self-citationCarr, D. B., Utzschneider, K. M., Hull, R. L., Kodama, K., Retzlaff, B. M., Brunzell, J. D., Shofer, J. B., Fish, B. E., Knopp, R. H., & Kahn, S. E. (2004) · Diabetes · doi:10.2337/diabetes.53.8.2087 · Cited by 993 · cited 1×
“First, the key metabolic dysfunction underlying MASLD is insulin resistance, and the selected metabolic risk factors do not equally predict insulin resistance, as, for example, diastolic blood pressure and HDL-C are only weakly associated with insulin resistance [18].”
Research works printed but not linked: 1
- Zobair, 2023, Lazarus and the Global NASH Council, Stigma in NAFLD and NASH: a global survey of patients and providers, Hepatology, 21
Cited by
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationDefinition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001186 · Cited by 1,405
Singal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Self-citation
Metadata
- Authors
- Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Castro Narro, G. E., Chowdhury, A., Cortez-Pinto, H., Cryer, D. R., Cusi, K., El-Kassas, M., Klein, S., Eskridge, W., Fan, J., Gawrieh, S., Guy, C. D., Harrison, S. A., Kim, S. U., Koot, B. G., Korenjak, M., Kowdley, K. V., Lacaille, F., Loomba, R., Mitchell-Thain, R., Morgan, T. R., Powell, E. E., Roden, M., Romero-Gómez, M., Silva, M., Singh, S. P., Sookoian, S. C., Spearman, C. W., Tiniakos, D., Valenti, L., Vos, M. B., Wong, V. W.-S., Xanthakos, S., Yilmaz, Y., Younossi, Z., Hobbs, A., Villota-Rivas, M., Newsome, P. N., & on behalf of the NAFLD Nomenclature consensus group
- Affiliations
- University of Chicago (US)
- City University of New York (US)
- Sorbonne Université (FR)
- University of Antwerp (BE)
- Virginia Commonwealth University (US)
- Michael E. DeBakey VA Medical Center (US)
- Mayo Clinic (US)
- Western University (CA)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France & HIFIH Laboratory UPRES EA3859, SFR 4208, Angers University, Angers, France
- University Hospital Southampton NHS Foundation Trust (GB)
- Latin American Association for the Study of the Liver (ALEH) Santiago, Chile
- Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
- Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt
- Washington University in St. Louis (US)
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Indiana University School of Medicine (US)
- Duke University Health System (US)
- University of Oxford (GB)
- Baylor College of Medicine (US)
- Hôpital Necker-Enfants Malades (FR)
- University of California San Diego (US)
- University of California, Irvine (US)
- Translational Research Institute (AU)
- Düsseldorf University Hospital (DE)
- Digestive Diseases and Ciberehd, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville (CSIC/HUVR/US), University of Seville, Seville, Spain
- Antwerp University Hospital (BE)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Cincinnati Children's Hospital Medical Center (US)
- Inova Health System (US)
- Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Corresponding author
- Newsome, Philip N.
- ORCID
- Rinella, Mary E.
- Lazarus, Jeffrey V.
- Ratziu, Vlad
- Francque, Sven M.
- Sanyal, Arun J.
- Kanwal, Fasiha
- Romero, Diana
- Abdelmalek, Manal F.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Arrese, Marco
- Bataller, Ramon
- Beuers, Ulrich
- Bugianesi, Elisabetta
- Byrne, Christopher D.
- Chowdhury, Abhijit
- Cryer, Donna R.
- Cusi, Kenneth
- Klein, Samuel
- Eskridge, Wayne
- Gawrieh, Samer
- Guy, Cynthia D.
- Harrison, Stephen A.
- Kim, Seung Up
- Koot, Bart G.
- Korenjak, Marko
- Kowdley, Kris V.
- Lacaille, Florence
- Loomba, Rohit
- Mitchell-Thain, Robert
- Morgan, Timothy R.
- Roden, Michael
- Silva, Marcelo
- Singh, Shivaram Prasad
- Sookoian, Silvia C.
- Spearman, C. Wendy
- Tiniakos, Dina
- Valenti, Luca
- Vos, Miriam B.
- Wong, Vincent Wai-Sun
- Xanthakos, Stavra
- Yilmaz, Yusuf
- Younossi, Zobair
- Newsome, Philip N.
- Venue
- Hepatology
- Published
- 2023-06-24
- Volume
- 78
- Issue
- 6
- Pages
- 1966-1986
- ISSN
- 0270-9139 (ISSN-L)
- PMC
- PMC10653297
- OpenAlex
- W4381681857
- Cited by
- 3,476
- References
- 34
- Citations by year
- 2026: 919 · 2025: 1158 · 2024: 1106 · 2023: 290
- FWCI
- 689.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Hepatology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by-nc-nd)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by-nc-nd)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-nd)
- HAL (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by-nc-nd)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by-nc-nd)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- American Association for the Study of Liver Diseases
- Gilead Sciences
- Alnylam Pharmaceuticals
- Celgene
- CSL Behring
- Regeneron Pharmaceuticals
- Verily Life Sciences
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (NIHR205082)
- Eisai
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF22OC0074397)
- Swedish Orphan Biovitrum
- Sun Pharma
- Genentech
- Allergan
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056341, K23DK131290)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, steatotic liver disease, MetALD, cardiometabolic risk factors, diagnostic criteria, patient advocacy, expert consensus
- MeSH terms
- Consensus Statements as Topic, Delphi Technique, Female, Hepatomegaly, Humans, Male, Surveys and Questionnaires, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A multisociety Delphi consensus statement on new fatty liver disease nomenclature. https://app.cochat.ai/papers/10.1097/hep.0000000000000520
- The paper
- Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., Arrese, M., Bataller, R., Beuers, U., Boursier, J., Bugianesi, E., Byrne, C. D., Castro Narro, G. E., Chowdhury, A., Cortez-Pinto, H., . . . on behalf of the NAFLD Nomenclature consensus group. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. https://doi.org/10.1097/hep.0000000000000520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.